FOLLOW US

Type 2 Diabetes Research Updates

For Medical Professionals

The U.S. Food and Drug Administration has approved a third glucagon-like peptide-1 (GLP-1) receptor antagonist—albiglutide—for use as an adjunct to diet and exercise in the treatment of type 2 diabetes.
Many pediatricians and family practice physicians recently surveyed were unaware that hemoglobin A1c is a recommended diagnostic test for type 2 diabetes; however, education on this recommendation was linked an increased number of physicians who said they would use the test in a hypothetical case involving an adolescent, according to a cross-sectional study in the February Journal of Adolescent Health.
Inpatient diabetes education was associated with 34% reduced risk of all-cause readmissions within 30 days, and 20% reduced risk of readmissions at 180 days, after adjustment for other potentially confounding variables, in a retrospective study published in Diabetes Care.
Sulfonylureas are as effective as dipeptidyl peptidase-4 (DDP-4) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists as second-line treatments for type 2 diabetes but at a lower cost, according to a study in February 26 issue of Diabetes Care.
The U.S. Food and Drug Administration (FDA) announced that it will evaluate clinical trial data from the manufacturer of saxagliptin (Onglyza and Kombiglyze XR) to investigate whether this medication is linked to an increased risk of heart failure.
Depression and impulse control disorders (eating disorders in particular) are independently associated with diagnosis of type 2 diabetes, according to a cross-sectional survey of adults published online ahead of print in Diabetologia.
Patients with both type 2 diabetes and thyroid cancer are more likely to achieve complete remission if they take metformin than if they do not, according to findings from a retrospective study published in the Journal of Clinical Endocrinology and Metabolism.
Managing adolescents with diabetes through the transition to adult care is challenging in terms of both the physical and psychosocial aspects of care.
Researchers have identified mutations in two genes that can cause neonatal diabetes.
The US Food and Drug Administration has approved Farxiga (dapaglifozin) as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes.
Despite recent advances in prevention and treatment of most diabetes-related vision loss, a study in JAMA Ophthalmology shows that less than half of people with diabetic macular edema know about the association between the diabetes and visual impairment.
People with diabetes have a higher rate of cancer compared to the general population, however, new evidence suggests that the type of anti-diabetic agent prescribed may impact this risk among women.
Data from a large cohort study of older patients with diabetes confirm recent treatment recommendations for this population—that focusing on blood pressure and cholesterol goals may be more beneficial than focusing on glycemic targets.
While widely used diabetes medications have similar effects on glucose control regardless of gender, these agents may have different effects on the hearts of men and women.
Study finds that younger and middle-age women with diabetes have similar heart disease risk factors as men—a 4-fold increase compared to women without diabetes. Aggressive screening and treatment urged.
Shared medical appointments are now being used to allow for more comprehensive diabetes care as well as social support, with the latest research showing significant improvements in glycemic control.
In a study involving more than 2,500 people, those with the highest magnesium intake had the lowest risk of developing type 2 diabetes over a 7-year period.
Large study shows no increased risk of myocardial infarction (heart attach), ischemic strokes, and death in over 16,000 patients treated with saxagliptin (Onglyza).
SHOW MAIN MENU
SHOW SUB MENU